Related Experiment Videos
Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study
Jae Seung Chang1,2, Tae Ho Kim1,2, Tuyet Thi Nguyen3
1Department of Physiology, Yonsei University Wonju College of Medicine, Wonju, Korea.
Geriatrics & Gerontology International
|April 11, 2017
Summary
Low levels of circulating irisin, a skeletal muscle peptide, are a sensitive marker for sarcopenia. This myokine can help predict muscle dysfunction and monitor age-related muscle changes.
Area of Science:
- Gerontology
- Muscle Physiology
- Biomarker Discovery
Background:
- Myokines are peptides released by skeletal muscle with potential as sarcopenia biomarkers.
- Irisin, a newly identified myokine, has an unclear role in pathological sarcopenia.
Purpose of the Study:
- To investigate the validity and accuracy of circulating irisin levels as a biomarker for sarcopenia.
- To assess the association between irisin levels and muscle atrophy and weakness.
Main Methods:
- Evaluated anthropometrics, body composition, and serum irisin levels in 715 community-dwelling Koreans.
- Diagnosed sarcopenia based on the Asian Working Group for Sarcopenia criteria for muscle atrophy and weakness.
Main Results:
- Circulating irisin levels correlated positively with appendicular lean mass/height² and handgrip strength in both sexes.
- Mean irisin levels were significantly lower in the sarcopenia group compared to the normal group.
- Low serum irisin concentration was a significant predictor of incident sarcopenia, even after adjusting for confounders (OR 0.20).
Conclusions:
- Low circulating irisin levels serve as a sensitive marker for muscle weakness and atrophy.
- Irisin shows potential as a biomarker for muscle dysfunction, aiding in the prediction and monitoring of sarcopenia.
- This research opens new avenues for understanding and managing age-related muscle decline.